Two GLP1 receptor agonists, liraglutide and recently semaglutide, have been approved in the United States and Europe for the treatment of obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) patients with comorbidities (high blood pressure, dyslipidemia, type 2 diabetes). Here, GLP1R is linked to type 2 diabetes mellitus.